Repair Bio advances plaque regression program with FDA nod

FDA RDEP eligibility for REP-0003 in HoFH strengthens a rare disease pathway with implications beyond inherited cholesterol disorders. For all the progress made in lowering cholesterol and reducing cardiovascular risk, medicine still has remarkably few options for removing the cellular damage that accumulates once atherosclerosis is established. That distinction lies at the heart of Repair […] The post Repair Bio advances plaque regression program with FDA nod appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.